Drew Ranieri
Stock Analyst at Morgan Stanley
(1.21)
# 3,522
Out of 4,876 analysts
164
Total ratings
43.82%
Success rate
-12.55%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $3.66 | +63.93% | 4 | Mar 5, 2025 | |
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $58.60 | +70.65% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $393.55 | +13.07% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $18.41 | +3.20% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $12.29 | +119.69% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $5.75 | +39.13% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $24.73 | -11.04% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $10.71 | -25.27% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $11.07 | +44.60% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $18.96 | +335.24% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $19.69 | +93.04% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $73.93 | +29.85% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $12.21 | +112.94% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $170.86 | +72.66% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $119.40 | +134.52% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.77 | -26.14% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $30.39 | +130.34% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $533.71 | -43.79% | 6 | Apr 25, 2022 |
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $3.66
Upside: +63.93%
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $58.60
Upside: +70.65%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $393.55
Upside: +13.07%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $18.41
Upside: +3.20%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $12.29
Upside: +119.69%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $5.75
Upside: +39.13%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $24.73
Upside: -11.04%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $10.71
Upside: -25.27%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $11.07
Upside: +44.60%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $18.96
Upside: +335.24%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $19.69
Upside: +93.04%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $73.93
Upside: +29.85%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $12.21
Upside: +112.94%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $170.86
Upside: +72.66%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $119.40
Upside: +134.52%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.77
Upside: -26.14%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $30.39
Upside: +130.34%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $533.71
Upside: -43.79%